Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus gemcitabine/cisplatin induction chemotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR1900023678Phase 4Not yet recruiting
- Sponsor
- Wuzhou Red Cross Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Wuzhou Red Cross Hospital. Primary endpoints: Objective response rate, Adverse reactions and 2 more. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
anlotinibgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900023678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023678.